Fulgent Genetics reports Q4 GAAP loss $128.1M; core revenue grows 21% YoY

Fulgent Genetics, Inc.

Full year total revenue $289.2M; core revenue (ex-COVID) grew 44% to $262.1M.
Q4 total revenue $70.5M; core revenue grew 21% to $66.5M.
Q4 GAAP net loss $128.1M ($4.30 per share); non-GAAP income $8.3M ($0.28 per share).
Full year GAAP net loss $167.8M ($5.63 per share); non-GAAP loss $12.3M ($0.41 per share).
Cash and investments $847.7M as of Dec 31, 2023; repurchased 953k shares for $25.1M in FY 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Fulgent Genetics, Inc. reported fiscal quarter and year ended December 31, 2023 results: revenue Total Revenue of $289.2 million, net income GAAP loss of $167.8 million, EPS $5.63 per share.

Period: fiscal quarter and year ended December 31, 2023
Revenue: Total Revenue of $289.2 million
Net income: GAAP loss of $167.8 million
EPS: $5.63 per share
Result: reported results

Exact text from the filing

Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results • Full Year 2023 Total Revenue of $289.2 million

View on SEC.gov

Browse all earnings releases →

Fulgent Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-021645

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.